Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ketotifen 4.0% Patch · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ketotifen 4.0% Patch |
| 2 | PLACEBO_COMPARATOR | Placebo Patch |
| 3 | ACTIVE_COMPARATOR | Pataday(TM) |
| 4 | PLACEBO_COMPARATOR | Placebo eye drops |
| Name | Type | Description |
|---|---|---|
| Ketotifen 4.0% Patch | DRUG | This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours. |
| Placebo | DRUG | The control is a placebo patch that contains only the inactive ingredients of ketotifen. |
| Olopatadine 0.2% | DRUG | 1 gtt/eye on two separate occasions |
| Artificial tears | DRUG | 1 gtt/eye on two separate occasions |
Inclusion Criteria: * 18 years of age of either sex and any race * positive history of ocular allergies and a positive skin test reaction to cat hair, cat dander, dog dander, grasses, ragweed, trees, dust mites, and/or cockroaches within the past 24 months * able and willing to avoid all disallowed...
Ketotifen 4.0% Patch is an investigational small molecule being developed for the treatment of allergic conjunctivitis. It is administered as a patch and is currently in Phase 2 clinical development. The drug is being evaluated for its safety and efficacy in patients with allergic conjunctivitis.
Ketotifen 4.0% Patch is being developed by BrainsWay Ltd., a company traded under the ticker BWAY. The company is conducting clinical trials to evaluate the patch for the treatment of allergic conjunctivitis.
Ketotifen 4.0% Patch is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its safety and efficacy in patients with allergic conjunctivitis.
Ketotifen 4.0% Patch has one completed Phase 2 clinical trial, identified as NCT00836485. This randomized, double-blind, placebo-controlled study enrolled 122 participants in the United States to evaluate the patch compared to placebo, olopatadine 0.2% ophthalmic solution, and artificial tears in the conjunctival allergen challenge model.
Ketotifen 4.0% Patch is a small molecule that is being developed for allergic conjunctivitis. The specific molecular target of the drug has not been disclosed in the available information, so its exact mechanism of action is not detailed here.